Recherche Fr menu ClientConnect
Recherche
Résultats
5 premiers résultats de la recherche Voir tous les résultats Recherche avancée
Recherches les plus fréquentes
Pages les plus visitées
    Référence: 20180623
    Date de publication: 12 avril 2019

    Promoteur – Intermédiaire Financier

    ADVICENNE SA

    Lieu

    Description

    The project supports the Promoter's research and development (R&D) investments to progress a pipeline of new therapeutics across the pharmaceutical value-chain.

    Objectifs

    R&D investments concern pediatric-friendly therapeutics adressing critical unmet medical needs in the field of rare and orphan diseases across the pharmaceutical value-chain.

    Secteur(s)

    • Services - Activités spécialisées, scientifiques et techniques

    Montant BEI envisagé (montant approximatif)

    EUR 20 million

    Coût total (montant approximatif)

    EUR 51 million

    Aspects environnementaux

    R&D investments are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.

    Passation des marchés

    The project promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus it is not covered by EU Directives on procurement. However, the Promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.

    Statut

    Signé - 2/07/2019

    Clause de non-responsabilité

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Mots-clés correspondants

    France Services